Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[41] Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
Chami, Perla
Diab, Youssef
Khalil, Danny N.
Azhari, Hassan
Jarnagin, William R.
Abou-Alfa, Ghassan K.
Harding, James J.
Hajj, Joseph
Ma, Jennifer
El Homsi, Maria
Reyngold, Marsha
Crane, Christopher
Hajj, Carla
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
[42] Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
Zhang, Jin
Hu, Changwei
Xie, Xiaoxiao
Qi, Linzhi
Li, Chuanzhou
Li, Shangze
VACCINES, 2023, 11 (03)
[43] Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors
Lin, Zuyuan
Lu, Di
Wei, Xuyong
Wang, Jianguo
Xu, Xiao
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1085 - 1102
[44] Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
Tamai, Yasuyuki
Fujiwara, Naoto
Tanaka, Takamitsu
Mizuno, Shugo
Nakagawa, Hayato
CANCERS, 2023, 15 (20)
[45] Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo, Alessandro
Cusmai, Antonio
Gadaleta-Caldarola, Gennaro
Palmiotti, Gennaro
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (04) : 333 - 339
[46] Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.
Personeni, Nicola
Pressiani, Tiziana
Capogreco, Antonio
Dal Buono, Arianna
D'Alessio, Antonio
Prete, Maria Giuseppina
Smiroldo, Valeria
Bozzarelli, Silvia
Giordano, Laura
Aghemo, Alessio
Santoro, Armando
Rimassa, Lorenza
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[47] Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors
Zhang, Rujia
Zhao, Haoran
Wang, Peng
Guo, Zuoming
Liu, Chunxun
Qu, Zhaowei
BMC CANCER, 2023, 23 (01)
[48] Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Yin, Xiaoqiang
Wu, Tongchui
Lan, Yadong
Yang, Wulin
BIOSCIENCE REPORTS, 2022, 42 (02)
[49] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
Federico, Piera
Petrillo, Angelica
Giordano, Pasqualina
Bosso, Davide
Fabbrocini, Antonietta
Ottaviano, Margaret
Rosanova, Mario
Silvestri, Antonia
Tufo, Andrea
Cozzolino, Antonio
Daniele, Bruno
CANCERS, 2020, 12 (10) : 1 - 20
[50] The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Hsu, Hsiao-Mei
Tsai, Hsin-, I
Lee, Wei-Chen
Wang, Chih-Chi
Yu, Ming-Chin
Lin, Shi-Ming
Lin, Chun-Yen
Wu, Chi-Huan
Lee, Chao-Wei
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1873 - 1880

← 1 2 3 4 5 →